Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dr. Emmanuel Barillot Receives Agilent Thought Leader Award

Published: Friday, August 30, 2013
Last Updated: Friday, August 30, 2013
Bookmark and Share
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.

Agilent Technologies Inc. has announced that Dr. Emmanuel Barillot, director of Bioinformatics and Systems IT at the Institut Curie in Paris, has received an Agilent Thought Leader Award in recognition of his pioneering development of user-friendly, Web-based bioinformatics tools for systems toxicology.

The award will support Dr. Barillot’s work in developing a database of cellular signaling pathways and a visualization tool to help the pharmaceutical industry develop more effective cancer treatments.

The new Web-based visualization tool will augment the institute’s Atlas of Cancer Signaling Networks and will be further enhanced by the combined capabilities of Curie’s NaviCell mapping tool and Agilent’s GeneSpring software and NMR technologies.

Together, these tools will enable researchers to identify off-pathway effects that could lead to undesirable outcomes, such as DNA damage.

“Assessing the safety and potential toxicity of drug candidates is a significant hurdle in the extraordinarily complex, labor-intensive drug development process,” said Tony Owen, Agilent’s senior director of life science marketing and market development.

Owen continued, “Pharmaceutical companies can spend many years and billions of dollars only to find that a once-promising preclinical therapeutic compound is actually harmful to patients in clinical tests. It is incumbent upon drug developers to find ways to assess drug toxicity much earlier in the process to reduce R&D time, minimize costs and maximize patient benefits.”

“The Agilent Thought Leader Award will accelerate the further development of the Curie Atlas of Cancer Signaling Networks, a comprehensive and freely available cancer pathway database, and NaviCell network visualization tool,” said Dr. Barillot. “These tools will enable earlier identification and visualization of toxic interactions between signaling pathways during the discovery and development of therapeutics for the treatment of cancer, thus enabling better informed drug-candidate selection and prioritization. They will also be useful for interpreting high-throughput biological data, like next-generation sequencing profiles of tumors or other samples.”

The Agilent Thought Leader Award promotes fundamental scientific advances by contributing financial support, products and expertise to the research of influential thought leaders in the life sciences and chemical analysis space.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
Centre for Genomic Research has become the UK's first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.
Wednesday, August 08, 2012
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Completes Acquisition of Dako, Danish Cancer Diagnostics Company
Acquisition to help strengthen Agilent's position in life sciences.
Thursday, June 28, 2012
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Friday, May 18, 2012
Agilent Appoints Molecular Genomics as its First Certified Service Provider for Microarrays in Singapore
Molecular Genomics offers microarray services using the Agilent CGH/SNP microarrays, gene expression, and microRNA products.
Monday, July 25, 2011
Agilent Appoints BGI First Certified Service Provider in China for Target Enrichment System for Next-Gen Sequencing
Certified for all SureSelect XT target enrichment protocols including human all-exon, SureSelect indexing, DNA capture, RNA capture, kinome RNA and custom kits.
Sunday, April 17, 2011
Agilent Technologies Acquire Lab901
Agilent Technologies Inc. announces that it has acquired the Edinburgh-based electrophoresis equipment and consumables company, Lab901.
Thursday, March 03, 2011
Agilent Debuts RNA Target Enrichment, Streamlining Transcriptome Profiling Studies to Advance Cancer and Stem Cell Research
Company has introduced SureSelect RNA Capture Kits, enabling geneticists to focus on specific genomic loci or transcripts of research interest.
Wednesday, February 09, 2011
Agilent Technologies Extends Million-Feature Format to Gene Expression Microarrays
Agilent SurePrint G3 Gene Expression Microarrays provides up to one million features per standard 1-by-3-inch slide for added throughput.
Tuesday, May 18, 2010
Scientific News
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Effects of Chemotherapy on Developing Ovaries in Female Fetuses
Researchers at University of Edinburgh have shown that etoposide can damage the development of the ovaries while a fetus is in the womb.
Breast Tumors Evolve in Response to Hormone Therapy
Researchers have suggested that analyzing a single sample of the breast tumor is insufficient for understanding how a patient should best be treated.
Cutting off the Cancer Fuel Supply
Research from investigators at Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy. The co-corresponding authors of the work are Rutgers Cancer Institute Deputy Director Eileen P. White, PhD, and researcher ‘Jessie’ Yanxiang Guo, PhD.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!